NeuroVision has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration.

Press Release

NeuroVision Imaging, Inc. (NeuroVision) is developing a breakthrough measurement of autofluorescence resulting from various pathological conditions in the retina including lipofuscin, amyloid beta (Aβ), collagen deposits, and vitelliform lesions.

Retinal Autofluorescence Measurement*

NeuroVision is engaged in clinical trials globally seeking to aid in disease diagnosis through retinal imaging.

Clinical Research

Our Story

NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease.   The company has developed a novel retinal imaging technology, that is incorporated into a number of clinical trials globally.

With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.